Search - tctmd.com

Displaying 1 - 20 of 38

Sort: Relevancy | Date

December 2022 News Roundup

News Opinion CV Team Dispatch

December 2022 News Roundup

December 28, 2022

Anatomic Disease After PCI Linked With Worse Outcomes: VA CART

News Daily News

Anatomic Disease After PCI Linked With Worse Outcomes: VA CART

Michael O'Riordan

December 22, 2022

CVD Claimed 20 Million Lives in 2021, but Disease Burden Varies Globally

News Daily News

CVD Claimed 20 Million Lives in 2021, but Disease Burden Varies Globally

Michael O'Riordan

December 14, 2022

Slight Risk of Interstitial Lung Disease Seen With Certain DOACs

News Daily News

Slight Risk of Interstitial Lung Disease Seen With Certain DOACs

November 23, 2022

RESPECT-EPA: Missed Primary Endpoint but Hints of Benefit With Icosapent Ethyl

News Conference News AHA 2022

RESPECT-EPA: Missed Primary Endpoint but Hints of Benefit With Icosapent Ethyl

November 10, 2022

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

News Conference News AHA 2022

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

Michael O'Riordan

November 05, 2022

Renal Function Affects Ticagrelor/Aspirin Impact on Recurrent Stroke: CHANCE-2

News Daily News

Renal Function Affects Ticagrelor/Aspirin Impact on Recurrent Stroke: CHANCE-2

Yael L. Maxwell

November 03, 2022

New Biomarker-Based Risk Score Performs Well in ACS

News Daily News

New Biomarker-Based Risk Score Performs Well in ACS

Michael O'Riordan

October 25, 2022

Apixaban Tops Rivaroxaban in AF Patients With Valve Disease, Claims Data Suggest

News Daily News

Apixaban Tops Rivaroxaban in AF Patients With Valve Disease, Claims Data Suggest

Michael O'Riordan

October 20, 2022

Sky-high Cost of SGLT2i and GLP1 Agonists Deter First-line Use

News Daily News

Sky-high Cost of SGLT2i and GLP1 Agonists Deter First-line Use

October 05, 2022

October 2022 News Roundup

News Opinion CV Team Dispatch

October 2022 News Roundup

October 01, 2022

Primordial Prevention Before End-stage CVD: Experts Call for a Fresh Focus

News Conference News TCT 2022

Primordial Prevention Before End-stage CVD: Experts Call for a Fresh Focus

Yael L. Maxwell

September 16, 2022

CV Care Around Noncardiac Surgery: New ESC Guidelines

News Conference News ESC 2022

CV Care Around Noncardiac Surgery: New ESC Guidelines

Michael O'Riordan

September 07, 2022

COVID-PACT: Full-Dose Anticoagulation Improves Outcomes in Critical COVID-19

News Conference News ESC 2022

COVID-PACT: Full-Dose Anticoagulation Improves Outcomes in Critical COVID-19

September 01, 2022

More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF

News Conference News ESC 2022

INVICTUS: More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF

Michael O'Riordan

August 28, 2022

Factor XIa Inhibitors Show Potential for Safer Anticoagulation After MI, Stroke

News Conference News ESC 2022

Factor XIa Inhibitors Show Potential for Safer Anticoagulation After MI, Stroke

August 28, 2022

ALL-HEART: Gout Drug Allopurinol No Help in CV Prevention

News Conference News ESC 2022

ALL-HEART: Gout Drug Allopurinol No Help in CV Prevention

August 27, 2022

Polypill Bests Usual Care in Patients With Recent MI: SECURE

News Conference News ESC 2022

Polypill Bests Usual Care in Patients With Recent MI: SECURE

Michael O'Riordan

August 26, 2022

TIME of Antihypertensive Dose Doesn’t Matter for CV Protection Open With no difference between nighttime and morning dosing, “patients can take their tablets whenever it’s convenient.” configuration options With no difference between nighttime and morning dosing, “patients can take their tablets whenever it’s convenient.”

News Conference News ESC 2022

TIME of Antihypertensive Dose Doesn’t Matter for CV Protection

August 26, 2022

What’s Going to Be Hot at ESC 2022?

News Opinion Editor's Corner ESC 2022

What’s Going to Be Hot at ESC 2022?

August 22, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.